Table 2.

Effect of Flavopiridol on s.c. Human Leukemia and Lymphoma Xenografts

Human Cell Line Mouse Strain Flavopiridol Treatment (days of treatment) 100% Tumor Regressions (50% regression) Tumor- Free >3 months Growth Delay (prob. value) Day Euthanasia (no. of mice)
HL-60 Promyelocytic Leukemia nu/nu Sham controls 1% DMSO0/6 (0/6) 0/6 20 (6/6)
20.6 mg/kg/d 72-h continuous infusion (days 10-13) 0/6 (0/6) 0/6 20.5% (P = .0248) 20 (6/6)
10.8 mg/kg/d 72-h continuous infusion (days 10-13) 0/6 (0/6) 0/6 17.2% (P = .0014) 20 (6/6)
Sham controls 1% DMSO 0/5 (0/5) 0/5 21 (4/5)
7.5 mg/kg/d bolus IV × 5 (days 13-17) 4/5 (1/5) 4/5 N/A >90 (5/6)
7.5 mg/kg/d IP × 5 (days 13-17) 6/6 (N/A) 6/6 N/A>90 (6/6)
SUDHL-4 Follicular Lymphoma SCIDSham controls 1% DMSO 0/5 (0/5) 0/5 38 (5/5)
7.5 mg/kg/d bolus IV × 5 (2 cycles) (days 25-30), and 38-42) 4/8 (2/8) 2/8 >73% (P = <.0001) 52 (8/8)
AS283 AIDS-Associated Lymphoma SCID Sham control 1% DMSON/A Early tumor 0/5 32 (5/5)
7.5 mg/kg/d bolus IV × 5 (2 cycles) (days 3-8, and 18-22)N/A Early tumor 0/7 >84% (P = <.0001) 32 (5/7)
Sham control 1% DMSO 0/5 0/5 20 (5/5)
7.5 mg/kg/d bolus IP × 5 (days 13-17) 1/6 (2/6) 0/6 45.8% (P = .013)  20 (6/6)
  • Abbreviation: N/A, not applicable.